Determining long-term efficacy for treatment of chronic pain in fibromyalgia patients

Affiliations

Comment

Leslie J Crofford. Pain. 2008.

. 2008 Aug 31;138(2):473-474.

doi: 10.1016/j.pain.2008.07.017. Epub 2008 Aug 5.

¹ Division of Rheumatology & Women's Health, University of Kentucky, Internal Medicine, J-503 Kentucky Clinic, 740 S. Limstone Dr., Lexington, KY 40536, USA.

No abstract available

Comment on

Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors.
Staud R, Price DD. Staud R, et al. Pain. 2008 Jun;136(3):232-234. doi: 10.1016/j.pain.2008.03.005. Epub 2008 Apr 1. Pain. 2008. PMID: 18384959 Free PMC article. No abstract available.
Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin.
Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, Sharma U. Crofford LJ, et al. Pain. 2008 Jun;136(3):419-431. doi: 10.1016/j.pain.2008.02.027. Epub 2008 Apr 8. Pain. 2008. PMID: 18400400 Clinical Trial.

1. Crofford LJ, Mease PM, Simpson S, Martin SA, Young JP Jr, Haig G, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month placebo-controlled, double-blind study with pregabalin. Pain. 2008;136:419-431.
1. Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain. 2008;136:232-234.
1. Woodcock J, Witter J, Dionne RA. Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev. 2007;6:703-710.